
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2090941/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The effect of duloxetine on mechanistic pain profiles, cognitive factors and clinical pain in patients with painful knee osteoarthritis—A randomized, <scp>doubleâ€blind</scp> , <scp>placeboâ€controlled</scp> , crossover study. European Journal of Pain, 2022, 26, 1650-1664.	2.8	12
2	Gastrointestinal pH, Motility Patterns, and Transit Times After Roux-en-Y Gastric Bypass. Obesity Surgery, 2021, 31, 2632-2640.	2.1	8
3	Oral absorption of oxycodone in patients with short bowel syndrome. Scandinavian Journal of Gastroenterology, 2021, 56, 1023-1029.	1.5	1
4	Effect of Rouxâ€enâ€Y gastric bypass on the pharmacokineticâ€pharmacodynamic relationships of liquid and controlledâ€release formulations of oxycodone. Basic and Clinical Pharmacology and Toxicology, 2021, 129, 232-245.	2.5	3
5	Opioid Specific Effects on Central Processing of Sensation and Pain: A Randomized, Cross-Over, Placebo-Controlled Study. Journal of Pain, 2021, 22, 1477-1496.	1.4	4
6	Pain medication use for musculoskeletal pain among children and adolescents: a systematic review. Scandinavian Journal of Pain, 2021, 21, 653-670.	1.3	13
7	Elderly patients with hip fracture and subnormal renal function have inadequate response to vitamin D supplementation. PharmaNutrition, 2021, 17, 100274.	1.7	0
8	Patient safety incidents involving transdermal opioids: data from the Danish Patient Safety Database. International Journal of Clinical Pharmacy, 2021, 43, 351-357.	2.1	4
9	Acute drug poisonings leading to hospitalization. Basic and Clinical Pharmacology and Toxicology, 2021, , .	2.5	5
10	A mechanism-based proof of concept study on the effects of duloxetine in patients with painful knee osteoarthritis. Trials, 2021, 22, 958.	1.6	4
11	Population pharmacokineticâ€pharmacodynamic modelling of liquid and controlledâ€release formulations of oxycodone in healthy volunteers. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 263-276.	2.5	13
12	Gastrointestinal pain. Nature Reviews Disease Primers, 2020, 6, 1.	30.5	246
13	Chronic abdominal pain and persistent opioid use after bariatric surgery. Scandinavian Journal of Pain, 2020, 20, 239-251.	1.3	15
14	The association between initial opioid type and long-term opioid use after hip fracture surgery in elderly opioid-naÃ <sup>-</sup> ve patients. Scandinavian Journal of Pain, 2020, 20, 755-764.	1.3	8
15	Emergency drug kits at the Danish hospital pharmacies: varying management and challenges. European Journal of Hospital Pharmacy, 2020, 27, 232-236.	1.1	0
16	Pain inhibitory mechanisms and response to weak analgesics in patients with knee osteoarthritis. European Journal of Pain, 2019, 23, 1904-1912.	2.8	38
17	Effects of Naloxegol on Gastrointestinal Transit and Colonic Fecal Volume in Healthy Participants Receiving Oxycodone. Journal of Neurogastroenterology and Motility, 2019, 25, 602-610.	2.4	11
18	Mechanism-based pain management in chronic pancreatitis – is it time for a paradigm shift?. Expert Review of Clinical Pharmacology, 2019, 12, 249-258.	3.1	22

ANNE ESTRUP OLESEN

#	Article	IF	CITATIONS
19	Pathophysiology and management of diabetic gastroenteropathy. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481985204.	3.2	26
20	Opioid use after hip fracture surgery: A Danish nationwide cohort study from 2005 to 2015. European Journal of Pain, 2019, 23, 1309-1317.	2.8	23
21	Mechanistic pain profiling as a tool to predict the efficacy of 3-week nonsteroidal anti-inflammatory drugs plus paracetamol in patients with painful knee osteoarthritis. Pain, 2019, 160, 486-492.	4.2	55
22	Patient and Disease Characteristics Associate With Sensory Testing Results in Chronic Pancreatitis. Clinical Journal of Pain, 2019, 35, 786-793.	1.9	16
23	A Pragmatic Utility Function to Describe the Risk-Benefit Composite of Opioid and Nonopioid Analgesic Medication. Journal of Pharmacology and Experimental Therapeutics, 2019, 371, 416-421.	2.5	6
24	Quantifying the Adequacy of Opioid Analgesic Consumption Globally: An Updated Method and Early Findings. American Journal of Public Health, 2019, 109, 52-57.	2.7	28
25	Differential effects of oxycodone and venlafaxine on resting state functional connectivity—A randomized placeboâ€controlled magnetic resonance imaging study. CNS Neuroscience and Therapeutics, 2018, 24, 820-827.	3.9	12
26	The Effect of a Combination of Diclofenac and Methadone Applied as Gel in a Human Experimental Pain Model – A Randomized, Placeboâ€controlled Trial. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 188-194.	2.5	12
27	The impact of naloxegol on anal sphincter function - Using a human experimental model of opioid-induced bowel dysfunction. European Journal of Pharmaceutical Sciences, 2018, 117, 187-192.	4.0	15
28	Association Between Genetic Polymorphisms and Pain Sensitivity in Patients with Hip Osteoarthritis. Pain Practice, 2018, 18, 587-596.	1.9	25
29	Comparison of subjective and objective measures of constipation – Employing a new method for categorizing gastrointestinal symptoms. Journal of Pharmacological and Toxicological Methods, 2018, 94, 23-28.	0.7	9
30	Offset Analgesia and The Impact of Treatment with Oxycodone and Venlafaxine: A Placeboâ€Controlled, Randomized Trial in Healthy Volunteers. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 727-731.	2.5	12
31	Offset analgesia is not affected by cold pressor induced analgesia. Scandinavian Journal of Pain, 2018, 18, 695-701.	1.3	3
32	Prediction of opioid dose in cancer pain patients using genetic profiling: not yet an option with support vector machine learning. BMC Research Notes, 2018, 11, 78.	1.4	15
33	Lack of genetic association between OCT1, ABCB1, and UGT2B7 variants and morphine pharmacokinetics. European Journal of Pharmaceutical Sciences, 2017, 99, 337-342.	4.0	22
34	Established and emerging methods for assessment of small and large intestinal motility. Neurogastroenterology and Motility, 2017, 29, e13008.	3.0	35
35	Genetic Influences of <i><scp>OPRM</scp>1</i> , <i><scp>OPRD</scp>1</i> and <i><scp>COMT</scp></i> on Morphine Analgesia in a Multiâ€Modal, Multiâ€Tissue Human Experimental Pain Model. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 6-12.	2.5	18
36	Objective methods for the assessment of the spinal and supraspinal effects of opioids. Scandinavian Journal of Pain, 2017, 14, 15-24.	1.3	13

#	Article	IF	CITATIONS
37	Cortical and spinal assessment - a comparative study using encephalography and the nociceptive withdrawal reflex. Journal of Pharmacological and Toxicological Methods, 2017, 84, 37-43.	0.7	3
38	Do genes affect morphine response?. Pharmacogenomics, 2017, 18, 1553-1555.	1.3	2
39	The impact of naloxegol treatment on gastrointestinal transit and colonic volume. Scandinavian Journal of Pain, 2017, 16, 172-172.	1.3	Ο
40	The effects of analgesics on central processing of tonic pain: AÂcross-over placebo controlled study. Neuropharmacology, 2017, 123, 455-464.	4.1	12
41	Predictors of opioid efficacy in patients with chronic pain: A prospective multicenter observational cohort study. PLoS ONE, 2017, 12, e0171723.	2.5	16
42	Management of chronic visceral pain. Pain Management, 2016, 6, 469-486.	1.5	24
43	Acute Metabolic Changes Associated With Analgesic Drugs: An MR Spectroscopy Study. Journal of Neuroimaging, 2016, 26, 545-551.	2.0	14
44	Association between Gene Polymorphisms and Pain Sensitivity Assessed in a Multiâ€Modal Multiâ€Tissue Human Experimental Model – An Explorative Study. Basic and Clinical Pharmacology and Toxicology, 2016, 119, 360-366.	2.5	8
45	Does catastrophic thinking enhance oesophageal pain sensitivity? An experimental investigation. European Journal of Pain, 2016, 20, 1214-1222.	2.8	4
46	A Model-Based Approach for Joint Analysis of Pain Intensity and Opioid Consumption in Postoperative Pain. AAPS Journal, 2016, 18, 1013-1022.	4.4	4
47	Venlafaxine and oxycodone effects on human spinal and supraspinal pain processing: a randomized crossâ€over trial. European Journal of Neuroscience, 2016, 44, 2966-2974.	2.6	10
48	Modelling the PKPD of oxycodone in experimental pain — Impact of opioid receptor polymorphisms. European Journal of Pharmaceutical Sciences, 2016, 86, 41-49.	4.0	3
49	Machine learning on encephalographic activity may predict opioid analgesia. European Journal of Pain, 2015, 19, 1552-1561.	2.8	30
50	The Effect of Oral Morphine on Pain-Related Brain Activation - An Experimental Functional Magnetic Resonance Imaging Study. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 316-322.	2.5	20
51	The genetic influences on oxycodone response characteristics in human experimental pain. Fundamental and Clinical Pharmacology, 2015, 29, 417-425.	1.9	24
52	Association Between Human Painâ€Related Genotypes and Variability in Opioid Analgesia: An Updated Review. Pain Practice, 2015, 15, 580-594.	1.9	56
53	Stochastic Pharmacokinetic–Pharmacodynamic Analysis of the Effect of Transdermal Buprenorphine on Electroencephalogram and Analgesia. Anesthesia and Analgesia, 2015, 121, 1165-1175.	2.2	5
54	Study protocol for a randomised, double-blinded, placebo-controlled, clinical trial of S-ketamine for pain treatment in patients with chronic pancreatitis (RESET trial). BMJ Open, 2015, 5, e007087-e007087.	1.9	16

#	Article	IF	CITATIONS
55	Evolving paradigms in the treatment of opioid-induced bowel dysfunction. Therapeutic Advances in Gastroenterology, 2015, 8, 360-372.	3.2	51
56	Multivariate Analysis of Single-Sweep Evoked Brain Potentials for Pharmaco-Electroencephalography. Neuropsychobiology, 2015, 71, 241-252.	1.9	1
57	Population pharmacokinetics of morphine and morphine-6-glucuronide following rectal administration – A dose escalation study. European Journal of Pharmaceutical Sciences, 2015, 68, 78-86.	4.0	8
58	Objective markers of the analgesic response to morphine in experimental pain research. Journal of Pharmacological and Toxicological Methods, 2015, 73, 7-14.	0.7	7
59	Randomized clinical trial: efficacy and safety of PPC-5650 on experimental esophageal pain and hyperalgesia in healthy volunteers. Scandinavian Journal of Gastroenterology, 2015, 50, 138-144.	1.5	14
60	Singleâ€sweep spectral analysis of contact heat evoked potentials: a novel approach to identify altered cortical processing after morphine treatment. British Journal of Clinical Pharmacology, 2015, 79, 926-936.	2.4	5
61	A review of morphine and morphine-6-glucuronide's pharmacokinetic–pharmacodynamic relationships in experimental and clinical pain. European Journal of Pharmaceutical Sciences, 2015, 74, 45-62.	4.0	92
62	Efficacy and Safety of PPCâ€5650 on Experimental Rectal Pain in Patients with Irritable Bowel Syndrome. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 140-145.	2.5	10
63	The effects of morphine and methylnaltrexone on gastrointestinal pain in healthy male participants. Neurogastroenterology and Motility, 2015, 27, 693-704.	3.0	3
64	Modelling concentration–analgesia relationships for morphine to evaluate experimental pain models. European Journal of Pharmaceutical Sciences, 2015, 66, 50-58.	4.0	10
65	Lessons Learned from Visceral Sensory Stimulation: Implications for Treatment of Chronic Abdominal Pain. , 2015, , 45-58.		0
66	Cingulate metabolites during pain and morphine treatment as assessed by magnetic resonance spectroscopy. Journal of Pain Research, 2014, 7, 269.	2.0	20
67	Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction. Clinical and Experimental Gastroenterology, 2014, 7, 345.	2.3	29
68	Sensitivity of quantitative sensory models to morphine analgesia in humans. Journal of Pain Research, 2014, 7, 717.	2.0	26
69	Morphine modifies the cingulate–operculum network underlying painful rectal evoked potentials. Neuropharmacology, 2014, 77, 422-427.	4.1	15
70	The Role of Pain Catastrophizing in Experimental Pain Perception. Pain Practice, 2014, 14, E136-45.	1.9	31
71	Gender, Variation in Opioid Receptor Genes and Sensitivity to Experimental Pain. Molecular Pain, 2013, 9, 1744-8069-9-20.	2.1	39
72	Morphine versus oxycodone analgesia after percutaneous kidney stone surgery. Urolithiasis, 2013, 41, 423-430.	2.0	20

5

#	Article	IF	CITATIONS
73	Prediction of postoperative pain after percutaneous nephrolithotomy: can preoperative experimental pain assessment identify patients at risk?. Urolithiasis, 2013, 41, 169-177.	2.0	17
74	A Population Pharmacokinetic and Pharmacodynamic Study of a Peripheral κ-Opioid Receptor Agonist CR665 and Oxycodone. Clinical Pharmacokinetics, 2013, 52, 125-137.	3.5	12
75	Somatosensory and trophic findings in the referred pain area in patients with kidney stone disease. Scandinavian Journal of Pain, 2013, 4, 165-170.	1.3	3
76	Can quantitative sensory testing predict responses to analgesic treatment?. European Journal of Pain, 2013, 17, 1267-1280.	2.8	72
77	Pharmacological challenges in chronic pancreatitis. World Journal of Gastroenterology, 2013, 19, 7302.	3.3	24
78	Advanced Pharmaco-EEG Reveals Morphine Induced Changes in the Brain's Pain Network. Journal of Clinical Neurophysiology, 2012, 29, 219-225.	1.7	13
79	Unravelling the Mystery of Capsaicin: A Tool to Understand and Treat Pain. Pharmacological Reviews, 2012, 64, 939-971.	16.0	271
80	Opioid-Induced Bowel Dysfunction. Drugs, 2012, 72, 1847-1865.	10.9	167
81	Human Experimental Pain Models for Assessing the Therapeutic Efficacy of Analgesic Drugs. Pharmacological Reviews, 2012, 64, 722-779.	16.0	185
82	The analgesic effect of pregabalin in patients with chronic pain is reflected by changes in pharmacoâ€EEG spectral indices. British Journal of Clinical Pharmacology, 2012, 73, 363-372.	2.4	60
83	The Absorption Profile of Pregabalin in Chronic Pancreatitis. Basic and Clinical Pharmacology and Toxicology, 2012, 111, 385-390.	2.5	8
84	Randomised clinical trial: pregabalin attenuates experimental visceral pain through sub-cortical mechanisms in patients with painful chronic pancreatitis. Alimentary Pharmacology and Therapeutics, 2011, 34, 878-887.	3.7	49
85	Is Electrical Brain Activity a Reliable Biomarker for Opioid Analgesia in the Gut?. Basic and Clinical Pharmacology and Toxicology, 2011, 109, 321-327.	2.5	14
86	Validated tools for evaluating opioid-induced bowel dysfunction. Advances in Therapy, 2011, 28, 279-294.	2.9	27
87	Central pain mechanisms following combined acid and capsaicin perfusion of the human oesophagus. European Journal of Pain, 2010, 14, 273-281.	2.8	37
88	Different effects of morphine and oxycodone in experimentally evoked hyperalgesia: a human translational study. British Journal of Clinical Pharmacology, 2010, 70, 189-200.	2.4	57
89	A Pharmacokinetic and Pharmacodynamic Study of Oral Oxycodone in a Human Experimental Pain Model of Hyperalgesia. Clinical Pharmacokinetics, 2010, 49, 817-827.	3.5	24
90	Translational pain research: Evaluating analgesic effect in experimental visceral pain models. World Journal of Gastroenterology, 2009, 15, 177.	3.3	14

#	Article	IF	CITATIONS
91	An endoscopic method for thermal and chemical stimulation of the human oesophagus. Neurogastroenterology and Motility, 2009, 21, 1250.	3.0	14
92	Assessing efficacy of nonâ€opioid analgesics in experimental pain models in healthy volunteers: an updated review. British Journal of Clinical Pharmacology, 2009, 68, 322-341.	2.4	73
93	Assessing analgesic actions of opioids by experimental pain models in healthy volunteers – an updated review. British Journal of Clinical Pharmacology, 2009, 68, 149-168.	2.4	109
94	Applying Concepts of Generalizability Theory on Data from Experimental Pain Studies to Investigate Reliability. Basic and Clinical Pharmacology and Toxicology, 2009, 105, 105-112.	2.5	8
95	Evoked Human Oesophageal Hyperalgesia: A Potential Tool for Analgesic Evaluation?. Basic and Clinical Pharmacology and Toxicology, 2009, 105, 126-136.	2.5	30
96	Analgesic Efficacy of Peripheral κ-Opioid Receptor Agonist CR665 Compared to Oxycodone in a Multi-modal, Multi-tissue Experimental Human Pain Model. Anesthesiology, 2009, 111, 616-624.	2.5	90
97	Effects of Paracetamol Combined with Dextromethorphan in Human Experimental Muscle and Skin Pain. Basic and Clinical Pharmacology and Toxicology, 2007, 101, 172-176.	2.5	8